Clinical Trials & Research

clinical trialsMany of today's most effective standard treatments are based on the results of previous clinical studies, and many cancer patients are now living longer because of progress made through clinical trials. Clinical trials offer high quality cancer care and also allow patients the opportunity to advance scientific knowledge and help future patients. Ongoing research is essential in the fight against cancer, and it is one of the major objectives of the Edwards Comprehensive Cancer Center.

The Charles H. McKown, Jr., MD, Translational Genomic Research Institute (TGRI), which is housed on the third floor of the Edwards Comprehensive Cancer Center, offers the appropriate environment for performing leading-edge cancer research and conducting clinical trials that are helping to shape the future of cancer research — and not just in Huntington.

ChemoID®, the first chemosensitivity assay against both cancer stem cells and bulk of tumor cells for patients, was developed by researchers, physicians and scientists working in the Translational Genomic Research Institute (TGRI) and it is now in use in the United States as well as other countries around the world.

“The goal of cancer research at the TGRI is to directly affect the disease outcome by taking innovative technologies and novel drugs from the bench to the bedside,” said Dr. Pier Paolo Claudio, who was instrumental in developing ChemoID®. “This approach saves lives and reduces healthcare costs. The research we conduct at the TGRI in collaboration with the Edwards Comprehensive Cancer Center will have a far-reaching impact on people suffering with cancer around the world.”

Clinical trials currently available

Code Description Type of cancer
Gait Analysis for Patients with Musculoskeletal Tumors. Supportive Care
2008P-000285 Biomechanics of Metastatic Defects in Bones. Supportive Care
A021202 Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors Neuroendocrine
ABI-007-MBC-001 A Phase II/III, Multi-Center, Open-Label, Randomized Study of Weekly Nab®- Paclitaxel in Combination with Gemcitabine or Carboplatin, Compared To Gemcitabine/Carboplatin, As First Line Treatment In Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer Breast Cancer
ALLIANCE A401202 A Randomized Phase III Study of Bendamustine + Rituximab vs. Ibrutinib + Rituximab vs. Irbrutinib Alone in Untreated Older Patients with CLL Leukemia/Lymphoma
B-49 A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer. Breast Cancer
BMS CA180-399 An Open Label, Randomized (2:1) Phase 2B Study of Dasatinib vs. Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved Optimal Response to 3 Months of Therapy with 400mg Imatinib Leukemia/Lymphoma
CA204-006 A Phase 3, Randomized, Open Label trial of Lenalidomide/dexamethasone With or without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma. Multiple Myeloma
CALGB 30901 Randomized Phase II Study of Maintenance Pemetrexed versus Observation for Patients with Malignant Pleural Mesothelioma Without Progression After First-line Chemotherapy Lung Cancer
CALGB-30607 Randomized, Phase III, Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer. Lung Cancer
CALGB-30801 A Randomized Ph III Double Blind Trial Evaluating Selective Cox-2 Inhibition in Cox 2 Expressing Advanced NSCLC. Lung Cancer
CALGB-80702 A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant Folfox Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer. Gastrointestinal Cancer
CALGB-90203 A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer. Genitourinary Cancer
CALGB-C90601 A Randomized Double-Blinded Phase III Study comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma. Genitourinary Cancer
E1505 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB - IIIA Non-Small Cell Lung Cancer (NSCLC). Lung Cancer
E1609 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma. Melanoma
E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer. Breast Cancer
E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer. Breast Cancer
E2905 Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia. Multiple Myeloma
N08C9 Randomized Study of Sulfasalazine versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Supportive Care
N093B Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer. Breast Cancer
NSABP B-43 A Phase III Clinical Trial Comparing Trastuzumab (Herceptin) Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy. Breast Cancer
NSABP B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cycloshospamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk node negative HER2-Low Invasive Breast Cancer. Breast Cancer
RTOG 1005 A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer. Breast Cancer
RTOG 1016 Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer. Head & Neck Cancer
RTOG 1203 A Randomized Phase III Study of Standard VS IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) Gynecologic Cancer
RTOG 1306 A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC) Lung Cancer
RU011201I A randomized Phase III Trial of Eribulin compared to standard weekly paclitaxel as first- or second-line therapy for locally recurrent or metastatic breast cancer (Eisai protocol # E7389-A001-303) Breast Cancer
S0819 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Lung Cancer
S0931 Renal Cell (GU)- EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study. Genitourinary Cancer
S1007 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. Breast Cancer
  • Page last updated: Jul 3, 2014
  • Share to Facebook Share to Twitter More...
Search in:

Show search options